Stereotaxis Announces Strategic Funding for Growth
Stereotaxis, Inc. (NASDAQ: STXS), a leading name in surgical robotics for minimally invasive endovascular procedures, has recently revealed its plans to raise $12.5 million through a registered direct offering of common stock. The share price has been set at $2.00, with significant backing from a strategic industry partner and selected institutional investors.
Utilization of Proceeds for Innovation
The funds generated from this offering are strategically earmarked to bolster the company’s balance sheet and facilitate the commercialization of their innovative strategies. David Fischel, the Chairman and CEO of Stereotaxis, expressed gratitude toward their supportive partners, stating, "The proceeds will significantly aid in accelerating product commercialization, crucial for our ongoing research and development efforts along with various corporate purposes." This initiative is particularly timely as the company navigates a pivotal year filled with potential breakthroughs in their technology.
Offering Details and Expectations
The gross proceeds from this initiative are anticipated to be around $12.5 million, although this figure will be subject to adjustments for placement agent fees and other associated expenses. The financing is structured in two parts, with an initial closing expected to bring in approximately $8.5 million, followed by a second closing projected to yield $4.0 million, all pending customary closing conditions. Lake Street Capital Markets LLC is designated as the exclusive placement agent for this offering.
Regulatory Compliance and Future Steps
The registered direct offering is being conducted in compliance with a previously filed shelf registration statement that was declared effective by the U.S. Securities and Exchange Commission. This ensures that the process abides by necessary regulatory standards and allows interested parties access to detailed documentation regarding the offering.
About Stereotaxis
Stereotaxis (NASDAQ: STXS) is renowned for its groundbreaking advancements in robotic surgical systems, designed to enhance the precision and safety of medical interventions. Their mission revolves around developing state-of-the-art instruments and information solutions tailored for interventional laboratories. With a track record of aiding over 150,000 patients globally, Stereotaxis is committed to extending access to minimally invasive treatments. The technology continues to revolutionize patient care settings and bolster operational productivity within healthcare environments.
Contact Information
If you need more information regarding this offering or the company, please reach out to:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
Phone: 314-678-6100
Email: investors@stereotaxis.com
Frequently Asked Questions
What is the purpose of the $12.5 million offering?
The funds are intended to strengthen Stereotaxis's balance sheet and accelerate their product commercialization strategy.
Who are the main investors in the offering?
A strategic industry partner, along with selected institutional investors, is leading the funding effort.
When is the initial closing for the offering?
The initial closing is expected around July 18, 2025.
What is Stereotaxis known for?
Stereotaxis is recognized as a pioneer in surgical robotics, specializing in minimally invasive endovascular interventions.
How can I get more information about Stereotaxis?
For additional details, contact the company via the provided email or phone number above.
